[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578990":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":20,"centralContacts":25,"locations":33,"responsibleParty":51,"collaborators":19,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":19,"eligibilityCriteria":59,"healthyVolunteers":56,"sex":60,"minAge":61,"maxAge":19,"enrollmentInfo":62,"targetDuration":19,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":19,"overallStatus":36,"whyStopped":19,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Bernstein Clinical Research Center","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"open-label administration","all subjects receive open-label lanadelumab",[12],"Biological: Lanadelumab 300 mg",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Lanadelumab 300 mg","no other intervention",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Jonathan Bernstein, MD","5139314181","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Karen Berendts","CONTACT","513-354-1746","kberendts@bernsteincrc.com",{"name":22,"role":28,"phone":19,"phoneExt":19,"email":32},"bernstja@ucmail.uc.edu",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Bernstein Clinical Research Center, LLC","RECRUITING","Cincinnati","Ohio","45236","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-84.51439,39.12711,{"lat":46,"lon":45},[49,50],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},{"name":22,"role":24,"phone":19,"phoneExt":19,"email":19},{"type":24,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Jonathan A. Bernstein, MD","PI\u002F Owner","100578990","phase-4-lanadelumab-in-long-term-prophylaxis-of-acquired-angioedema-100578990",false,"NCT06818474","Lanadelumab in Long-term Prophylaxis of Acquired Angioedema","Inclusion Criteria:\n\n* A diagnosis of AAE with recurrent attacks without urticaria (decreased C1INH functional, quantitative levels, decreased C4 and decreased C1q levels, no family history of angioedema), presence of anti-C1INH antibody and\u002For paraproteinemia (e.g. monoclonal gammopathy of unknown significance)\n* historical attack rate of \\>= on attack per month prior to starting tranexamic acid (TAA)\n\nExclusion Criteria:\n\n* History of anaphylaxis or hypersensitivity to biologics\n* History of major systemic disease not well controlled in opinion of the PI\n* Women who are pregnant or breast feeding\n* Concurrent participation in other clinical trials\n* HAE Type 1 or 2 and normal complement HAE","ALL","18 Years",{"count":63,"type":64},5,"ESTIMATED","INTERVENTIONAL",[67],"PHASE4","use of lanadelumab in patients with acquired angioedema",[70],"Angioedema","2025-02-24",{"date":73,"type":74},"2025-02-25","ACTUAL",{"date":76,"type":74},"2024-06-01",{"date":78,"type":64},"2027-12-01",{"name":5,"class":6},1]